Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Graham Capital Management L.P.

Graham Capital Management L.P. cut its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 54.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,232 shares of the company's stock after selling 1,481 shares during the period. Graham Capital Management L.P.'s holdings in Medpace were worth $409,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of MEDP. Invesco Ltd. lifted its holdings in Medpace by 91.8% during the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after purchasing an additional 519,186 shares in the last quarter. Proficio Capital Partners LLC raised its position in shares of Medpace by 34,497.4% during the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock valued at $80,575,000 after purchasing an additional 241,827 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Medpace during the 4th quarter valued at $78,144,000. Norges Bank purchased a new position in shares of Medpace during the 4th quarter valued at $69,859,000. Finally, GW&K Investment Management LLC boosted its holdings in Medpace by 93.9% in the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock worth $91,516,000 after buying an additional 133,379 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Analysts Set New Price Targets

MEDP has been the topic of a number of recent analyst reports. Robert W. Baird decreased their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Truist Financial decreased their target price on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research note on Wednesday, April 23rd. Leerink Partnrs raised Medpace to a "hold" rating in a report on Monday, March 24th. William Blair reaffirmed a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Finally, Leerink Partners began coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, Medpace has a consensus rating of "Hold" and a consensus target price of $349.30.

Medpace Trading Up 0.2%

NASDAQ:MEDP traded up $0.70 during trading hours on Thursday, hitting $296.47. 60,914 shares of the stock were exchanged, compared to its average volume of 350,784. The firm's fifty day moving average price is $303.06 and its 200 day moving average price is $327.40. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $459.77. The company has a market cap of $8.52 billion, a P/E ratio of 23.38, a P/E/G ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The company had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. During the same quarter last year, the firm posted $3.20 EPS. Equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares of the company's stock, valued at $904,856.36. This trade represents a 36.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 20.30% of the company's stock.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.